OrderlyMeds announces a new guide translating cognitive decline research into practical strategies for brain aging prevention through weight loss, metabolic health, diet, physical activity, and sleep interventions backed by scientific evidence.
-- OrderlyMeds has published a new guide translating cognitive decline research into actionable strategies that address modifiable factors directly impacting brain aging. The resource focuses on metabolic health, diet, physical activity, and sleep—controllable elements backed by scientific evidence—and is designed for adults seeking prevention-focused approaches to neurodegenerative conditions. By synthesizing emerging research into practical recommendations, the company aims to empower individuals with tools to influence their cognitive trajectory through structured lifestyle and weight management interventions.
More information is available at https://orderlymeds.com/resources/slow-down-your-brain-aging/
According to the Centers for Disease Control and Prevention and the Alzheimer's Association, approximately 7 million Americans aged 65 and older are living with Alzheimer's dementia today. Recent research from Medical News Today indicates that nearly 40% of dementia cases are influenced by modifiable lifestyle factors—such as weight and activity levels—rather than genetics, positioning daily choices as a powerful lever for prevention.
Through structured weight management programs, OrderlyMeds combines nutritional guidance, lifestyle education, and medical oversight. Emerging clinical research on GLP-1 receptor agonists—medications often used for weight management—has shown potential to reduce Alzheimer's risk by up to 70%, while a Phase 2b trial demonstrated that liraglutide reduced brain shrinkage in memory and decision-making regions by nearly 50% compared to placebo. These findings validate the connection between weight management and brain-protective outcomes, positioning metabolic intervention as a concrete pathway to slowing cognitive aging.
OrderlyMeds' guide's impact is amplified through a partnership with NeuroAge Therapeutics, which provides personalized brain health measurement and planning. The NeuroAge Test integrates AI-powered MRI analysis, blood biomarkers, cognitive performance testing, and genetic data to deliver individualized, science-backed strategies for influencing biological brain age. This collaboration transforms general recommendations into tailored interventions, addressing the target audience's need for measurable, evidence-based approaches to cognitive preservation.
Research suggests that even modest weight reductions—approximately one percent of body mass—correlate with slower progression of cognitive aging markers, with some individuals showing brain-aging measures consistent with being several months younger. This finding demonstrates that sustained, incremental effort yields tangible neurological benefits, reinforcing the new guide's promise that accessible lifestyle changes can produce measurable cognitive outcomes.
Adults interested in accessing the guide and learning about OrderlyMeds' weight management programs can visit the company's website at https://orderlymeds.com/
Contact Info:
Name: Annie Dawson
Email: Send Email
Organization: OrderlyMeds
Address: 235 Ponce De Leon Pl Suite M347, Decatur, Georgia 30030, United States
Website: https://orderlymeds.com/
Source: PressCable
Release ID: 89185927
If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release, or if there is a need for a press release takedown, we urge you to notify us without delay at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond within 8 hours – ensuring swift resolution of identified issues or offering guidance on removal procedures. Delivering accurate and reliable information is fundamental to our mission.
